Scholarlink

<p>Herpes zoster is the secondary manifestation of an infection with the ubiquitous varicella zoster virus and primarily affects immunocompromised and older individuals. The skin lesions caused by the virus are typically clusters of blisters on a&#xa0;reddened base and affect the skin within the corresponding dermatome, meaning the rash is usually unilateral. While the primary manifestation (chickenpox) in childhood usually resolves quickly without intervention, in cases of herpes zoster treatment with antiviral medications should be initiated early to prevent complications. The primary goal here is preventing postherpetic neuralgia (PHN), a&#xa0;painful nerve irritation where treatment often poses a&#xa0;protracted challenge for patients and healthcare providers. Treatment options for PHN are outlined here. Vaccination against herpes zoster is recommended for immunocompromised individuals and those over the age of&#xa0;60 years and is available free of charge in Austria since November 2025.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Herpes Zoster und Post-Zoster-Neuralgie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Daisy Kopera

摘要

Herpes zoster is the secondary manifestation of an infection with the ubiquitous varicella zoster virus and primarily affects immunocompromised and older individuals. The skin lesions caused by the virus are typically clusters of blisters on a reddened base and affect the skin within the corresponding dermatome, meaning the rash is usually unilateral. While the primary manifestation (chickenpox) in childhood usually resolves quickly without intervention, in cases of herpes zoster treatment with antiviral medications should be initiated early to prevent complications. The primary goal here is preventing postherpetic neuralgia (PHN), a painful nerve irritation where treatment often poses a protracted challenge for patients and healthcare providers. Treatment options for PHN are outlined here. Vaccination against herpes zoster is recommended for immunocompromised individuals and those over the age of 60 years and is available free of charge in Austria since November 2025.